In Depth 31 Mar 2023 How has the collapse of the Silicon Valley Bank affected the biotech industry? When investors got wind of Silicon Valley Bank (SVB) being forced to sell its treasury bonds at a loss, owing in part to surging interest rates in the past year – a move by the Federal Reserve to counteract rising inflation – panic followed a bank run. And in a swift spur of events, the […] March 31, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 31 Mar 2023Beyond Biotech podcast 40: Antibody-drug conjugates This episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, chief scientific of Nectin Therapeutics, and Matthew Robinson, chief technology officer of Immunome. This episode of the podcast is sponsored by PHTA. Immunome Immunome’s Discovery Engine leverages the information stored in memory B cells to […] March 31, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 Vaccitech announces positive topline data for chronic hepatitis study Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat and cure chronic infectious diseases, […] March 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 Could new riboswitch make gene therapy safer? Turning genes on and off as easily and predictably as flicking a switch could be a powerful tool in medicine and biotech. A type of technology called a riboswitch might be the key.The Okinawa Institute of Science and Technology (OIST) in Japan, in collaboration with Astellas Pharma Inc., has developed a new toolkit that uses […] March 30, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 SR One closes biotech fund at $600M SR One, a transatlantic life sciences investment firm, has announced the close of its second fund at more than $600 million, exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm. The diverse investor base of […] March 30, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2023 Pharming immunodeficiency drug given FDA approval Pharming Group N.V. has announced that the US Food and Drug Administration (FDA) has approved Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Pharming’s Joenja, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the […] March 29, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Mar 2023 5 hearing loss biotech companies you should know about More than 1.5 billion people – nearly 20% of the world’s population – live with hearing loss globally, with 430 million suffering from disabling hearing loss. In this article, we take a look at five of the top hearing loss companies making efforts to reduce these figures. According to the World Health Organization (WHO), nearly […] March 29, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Inside Labiotech 28 Mar 2023 Noticed something different? Labiotech is getting a new look for 2023! Hi there, dear readers! I know, it’s been a while since we posted “behind the scene” updates from Labiotech so I’m sure you’re curious to know what we’ve been cooking during the past few months. Well, the reason is simple, we’ve been working hard on a whole new design for the website! With this new […] March 28, 2023 - 3 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
Infographics by Merck 28 Mar 2023 Infographic: Why choosing a client-centric CTDMO is critical when outsourcing biomanufacturing projects In 2021, 28% of FDA approvals were granted to biologic drugs, showcasing the increasing demand for the biopharma industry to develop, manufacture and market biologic-based therapies. Biologic drugs include monoclonal antibodies and large molecules produced in mammalian cells, bringing the already complex process of drug development to a new level. Although the biomanufacturing of many […] March 28, 2023 - 2 minutesmins - By Maya Chergova Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023Beyond Biotech podcast 39: World Tuberculosis Day March 24 is World Tuberculosis Day. To mark the occasion, we have conversations with Christopher Fox, senior vice president, formulations, at the Access to Advanced Health Institute; TB Alliance CEO Mel Spigelman; and Jane Theaker, CEO of PBD Biotech. This episode of the podcast is sponsored by Samplix. World Tuberculosis Day Tuberculosis is a leading […] March 24, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Evotec receives $6.6M for tuberculosis drug discovery On World Tuberculosis Day, Evotec SE has announced that it has received a $ 6.6 million grant from The Bill & Melinda Gates Foundation for drug discovery to tackle tuberculosis. The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the company to progress a portfolio of TB […] March 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Metabolism of RNA linked to leukemia Researchers at Lund University Faculty of Medicine in Sweden have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome patients, MDS. In a study published in the Molecular Cell journal, they explain what makes hematopoietic stem cells acquire malignant traits in cancer. RNA splicing is […] March 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email